Edition:
United Kingdom

Atara Biotherapeutics Inc (ATRA.OQ)

ATRA.OQ on NASDAQ Stock Exchange Global Select Market

45.40USD
16 Feb 2018
Change (% chg)

$-1.65 (-3.51%)
Prev Close
$47.05
Open
$46.50
Day's High
$49.25
Day's Low
$44.15
Volume
271,977
Avg. Vol
152,276
52-wk High
$49.90
52-wk Low
$11.80

Chart for

About

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or... (more)

Overall

Beta: --
Market Cap(Mil.): $495.06
Shares Outstanding(Mil.): 30.56
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.64
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Atara Biotherapeutics Gets FDA Clearance To Proceed With Multiple Sclerosis study

* ATARA BIOTHERAPEUTICS ANNOUNCES FDA CLEARANCE TO PROCEED WITH ENROLLMENT AT U.S. SITES FOR ONGOING GLOBAL PHASE 1 CLINICAL STUDY TO EVALUATE ATA188 IN PATIENTS WITH PROGRESSIVE OR RELAPSING-REMITTING MULTIPLE SCLEROSIS

10 Jan 2018

BRIEF-Camber Capital Management Reports 6.7 Pct Passive Stake In Atara Biotherapeutics

* CAMBER CAPITAL MANAGEMENT LLC REPORTS A 6.7 PERCENT PASSIVE STAKE IN ATARA BIOTHERAPEUTICS AS OF JANUARY 04 - SEC FILING Source text : ( http://bit.ly/2m1PfiG ) Further company coverage:

05 Jan 2018

BRIEF-Atara Biotherapeutics Announces Proposed Offering Of Common Stock

* ATARA BIOTHERAPEUTICS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK

02 Jan 2018

BRIEF-Atara Biotherapeutics Gets FDA Clearance To Initiate Two Phase 3 Clinical Studies To Evaluate Tabelecleucel

* ATARA BIOTHERAPEUTICS ANNOUNCES FDA CLEARANCE TO INITIATE TWO PHASE 3 CLINICAL STUDIES TO EVALUATE TABELECLEUCEL IN PATIENTS WITH RITUXIMAB-REFRACTORY EPSTEIN-BARR VIRUS ASSOCIATED POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (EBV+PTLD)

29 Dec 2017

BRIEF-Morgan Stanley Reports 5 Pct Passive Stake In Atara Biotherapeutics As Of Nov 27

* MORGAN STANLEY REPORTS 5.0 PERCENT PASSIVE STAKE IN ATARA BIOTHERAPEUTICS INC AS OF NOVEMBER 27 - SEC FILING Source text: (http://bit.ly/2jrEZiq) Further company coverage:

07 Dec 2017

BRIEF-Atara Biotherapeutics reports Q3 loss per share $1.02

* Atara Biotherapeutics Inc announces third quarter 2017 financial results and recent highlights

09 Nov 2017

BRIEF-Atara Biotherapeutics receives rare pediatric disease designation from FDA for Ata230

* Atara Biotherapeutics receives rare pediatric disease designation from FDA for Ata230 for treatment of congenital cytomegalovirus (CMV) infection Source text for Eikon: Further company coverage:

26 Oct 2017

BRIEF-Atara Biotherapeutics announces abstract publication for two MSParis2017 congress presentations

* Atara Biotherapeutics announces abstract publication for two MSParis2017 congress presentations, including updated interim results from a phase 1 study of autologous ATA190 in patients with progressive multiple sclerosis (MS)

16 Oct 2017

BRIEF-Atara Biotherapeutics Inc - ‍announced receipt of positive regulatory feedback from Health Canada for ATA129​

* Atara Biotherapeutics Inc - ‍announced receipt of positive regulatory feedback from Health Canada for ATA129​

11 Sep 2017

BRIEF-Atara Biotherapeutics receives FDA orphan drug designation for ATA230

* Atara Biotherapeutics receives FDA orphan drug designation for ata230

05 Sep 2017

Competitors

  Price Chg
Biogen Inc (BIIB.OQ) $291.87 -7.51
Bayer AG (BAYGn.DE) €98.54 +1.15
Bayer AG (BAYE.F) -- --
Teva Pharmaceutical Industries Limited (TEVA.TA) 7,430.00 +764.00
Merck KGaA (MRCG.DE) €83.52 +1.00
Sanofi SA (SASY.PA) €64.50 +1.00
Novartis AG (NOVN.S) CHF80.80 +1.18
Roche Holding Ltd. (ROG.S) CHF225.50 +2.10
Roche Holding Ltd. (RO.S) CHF230.20 +2.60

Earnings vs. Estimates